Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancer

17 Jan 2024

Abstract excerpt

In this study, we aimed to address the current limitations of therapies for macro-metastatic triple-negative breast cancer (TNBC) and provide a therapeutic lead that overcomes the high degree of heterogeneity associated with this disease. Specifically, we focused on well-documented but clinically underexploited cancer-fueling perturbations in mRNA translation as a potential therapeutic vulnerability. We therefore...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to RNA and protein synthesis mechanisms
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38232291
DOI: 10.1073/pnas.2318093121

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A second-generation eIF4A RNA helicase inhibitor exploits translational reprogramming as a vulnerability in triple-negative breast cancerPMID 38232291Read ↗

Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer modelsSemantic proximity Read ↗

eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancerSemantic proximity Read ↗

Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast CancerSemantic proximity Read ↗

Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibitionSemantic proximity Read ↗

Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancerSemantic proximity Read ↗

The malignant phenotype in breast cancer is driven by eIF4A1-mediated changes in the translational landscape.Semantic proximity Read ↗

Fibrillarin-mediated ribosomal RNA maturation is a novel therapeutic vulnerability in triple-negative breast cancerSemantic proximity Read ↗

Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast CancerSemantic proximity Read ↗

Selective mRNA translation determines adaptative mutability of melanoma cells to anti-BRAF/MEK combination therapy.Semantic proximity Read ↗

Ribosome Profiling Reveals Translational Reprogramming via mTOR Activation in Omacetaxine Resistant Multiple MyelomaSemantic proximity Read ↗

CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A.Semantic proximity Read ↗

Programmable translational inhibition by a molecular glue-oligonucleotide conjugateSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.